PRESS

April 2025

AustinPx Launches KinetiSol™ Equipment Lease Program

October 2024

AustinPx Wins Accelerating Innovation Award for KinetiSol™ Technology at the 2024 CPHI Pharma Awards

April 2024

AustinPx Invests in Pharmaceutics and Manufacturing Capabilities to Accelerate Drug Development

March 2024

Elizabeth Hickman to Succeed Tim Scott as AustinPx CEO

January 2024

AustinPx Partners with Microsize on KinetiSol™ Technology

May 2023

AustinPx Expands Development and Manufacturing Technologies

March 2023

Amorphous Solid Dispersions: Development Trends, Challenges and the Future, Upcoming Webinar Hosted by Xtalks 

October 2022

AustinPx Names Derek Hennecke and Marshall Crew to its Board of Directors

September 2022

AustinPx Names Elizabeth Hickman Chief Business Officer; Company Increases Leadership Ranks to Accelerate Company’s CDMO Transformation

August 2022

DisperSol appoints Tim Scott new President and CEO; Company changes name to AustinPx™, Pharmaceutics and Manufacturing

August 2021

DisperSol and Catalent Collaborate to Establish KinetiSol™ Technology Manufacturing Hub for DisperSol Pharmaceutical Pipeline

July 2021

DisperSol Technologies Promotes Chris Brough to Chief Technology Officer

DisperSol Technologies Promotes Dave Miller to Chief Scientific Officer

April 2018

DisperSol Technologies Raising $27 Million and Initiating Phase II trials of DST-0509 in Iron Overload Disorder

November 2017

DisperSol Technologies Announces New R&D Data to Be Presented at 2017 Annual Meeting of AAPS

November 2016

DisperSol Names Dr. Edward M. Rudnic as Chief Executive Officer, RCT Leads $12 Million Funding Round

February 2015

DisperSol Technologies Secures over $10 Million with the Close of Financing Led by Research Corporation Technologies